---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-110385"
form_type: "8-K"
ticker: "ADIL"
cik: "0001513525"
company_name: "ADIAL PHARMACEUTICALS, INC."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:50:31.545417+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Adial reports Q3 net loss $1.8M, cash $4.6M; FDA provides Phase 3 guidance for AD04

## Summary
- Net loss $1.8M for Q3 2025 vs $2.2M in Q3 2024; R&D expenses down 50% YoY.
- Cash and equivalents $4.6M at Sep 30, 2025; runway into Q2 2026.
- Successful End of Phase 2 meeting with FDA; obtained guidance on Phase 3 design for AD04 (AUD).
- Analytical validation of cheek swab test with Genomind for biomarker-positive patients; FDA confirmed NSR, no IDE needed.
- Patent protection extended to at least 2045 via provisional patent update filed July 2025.

## SEC filing metadata
- accession: 0001213900-25-110385
- form_type: 8-K
- ticker: ADIL
- cik: 0001513525
- company_name: ADIAL PHARMACEUTICALS, INC.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1513525/000121390025110385/0001213900-25-110385-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1513525/000121390025110385/ea0265418-8k_adial.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-110385
- JSON: https://secwatch.observer/filing/0001213900-25-110385.json
- Plain text: https://secwatch.observer/filing/0001213900-25-110385.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.